Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ciclopirox-based therapy versus amorolfine alone for toenail dermatophytic onychomycosis
2009-011125-14Phase 4Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2009
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of RV4104A, ciclopirox and amorolfine in onychomycosis (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Treatment success at endpoint. Started May 2009; status: completed.
02
Drugs
RV4104Aciclopiroxamorolfine
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2009-011125-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011125-14.